“Landmark Trial” of the New Cardiovascular Drug Finerenone-Not!!
Finerenone (Kerendia) is a new drug that is prescribed to slow the progression of chronic kidney disease and the risk of cardiovascular death, non-fatal heart attack, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes. The retail price o…
Keep reading with a 7-day free trial
Subscribe to Slow Aging and Delay Chronic Disease Development to keep reading this post and get 7 days of free access to the full post archives.